Last reviewed · How we verify
Concomitant therapy 14 days
Concomitant therapy 14 days is a SGLT2 inhibitor Small molecule drug developed by Incheon St.Mary's Hospital. It is currently FDA-approved for Type 2 diabetes, Heart failure.
This drug is used to treat various conditions by inhibiting the reabsorption of sodium and water in the kidneys.
This drug is used to treat various conditions by inhibiting the reabsorption of sodium and water in the kidneys. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | Concomitant therapy 14 days |
|---|---|
| Sponsor | Incheon St.Mary's Hospital |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
The exact mechanism of action is through the inhibition of the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, leading to reduced glucose reabsorption and increased glucose excretion in the urine. This results in improved glycemic control and weight loss in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Increased risk of diabetic ketoacidosis
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Increased risk of hypotension
- Increased risk of acute kidney injury
Key clinical trials
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer (NA)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Effects of Auricular Point Pressing With Pellets in Children With Insufficient Hyperopia Reserve (NA)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (PHASE2)
- A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection (NA)
- FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Concomitant therapy 14 days CI brief — competitive landscape report
- Concomitant therapy 14 days updates RSS · CI watch RSS
- Incheon St.Mary's Hospital portfolio CI
Frequently asked questions about Concomitant therapy 14 days
What is Concomitant therapy 14 days?
How does Concomitant therapy 14 days work?
What is Concomitant therapy 14 days used for?
Who makes Concomitant therapy 14 days?
What drug class is Concomitant therapy 14 days in?
What development phase is Concomitant therapy 14 days in?
What are the side effects of Concomitant therapy 14 days?
What does Concomitant therapy 14 days target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2
- Manufacturer: Incheon St.Mary's Hospital — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Indication: Drugs for Heart failure
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing